#ESMO26：在接受放疗的极高危、局限性和复发性 #ProstateCancer 患者中，II 期 DASL-HiCaP #ClinicalTrial 显示了强化系统治疗的获益。与标准治疗相比，在放疗和雄激素剥夺治疗（#ADP）基础上加用雄激素受体通路抑制剂（#ARPI）darolutamide，可获得更优的 4 年无转移生存率，这进一步支持了 STAMPEDE 试验的早期证据。
PROTEUS II 期试验的一项亚组研究显示，在接受根治性前列腺切除术的局限性高危前列腺癌患者中，围手术期在雄激素剥夺治疗（#ADP）基础上使用 ARPI apalutamide，与根治性前列腺切除术联合盆腔淋巴结清扫术相比，可获得更优的无事件生存率、无转移生存率以及至后续治疗的时间。
阅读最新新闻：https://ow.ly/jIi850ZZYxe
#InsightsbyESMO #CancerResearch #MedicalOncology
118 浏览 · 0 赞 · 0 转发 · 0 回复
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgPerioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.orgDarolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 t
https://esmocongress.esmo.org来源：ESMO - Eur. Oncology · x.com